LIBTAYO's robust efficacy in high-risk CSCC and potential blockbuster status ... There are presently 11 Phase III studies being explored in a diverse array of disease areas that may be further ...

More growth potential is possible as the company pointed to positive data posted for adjuvant use of Libtayo in patients with cutaneous squamous cell carcinoma (CSCC). With that result ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

With no currently approved options in the adjuvant setting, these landmark results demonstrate Libtayo could represent a major advance in delaying recurrence in these vulnerable patients.” C-POST ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The C-POST study involved 415 patients who were ... in the first half of 2025. Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new ...

Updated results from the study ... Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for an uncommon skin cancer called cutaneous squamous cell carcinoma ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

The C-POST study involved 415 patients ... in the first half of 2025. Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new ...